The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Genomic determinants of outcome in acute lymphoblastic leukemia: A Children’s Oncology Group study.
 
Ti-Cheng Chang
No Relationships to Disclose
 
Wenan Chen
Stock and Other Ownership Interests - 10X Genomics; Illumina
 
Abdelrahman Elsayed
Patents, Royalties, Other Intellectual Property - I have two patent applications: Patent 1: Title: "Pharmacogenomics score to make decisions on therapy augmentation in AML”; Status: Filed; Number: US Provisional Application No.: 63/233,673 Patent 2: Title: “ Methods for Predicting AML Outcome”; Status:
 
Stanley B. Pounds
Patents, Royalties, Other Intellectual Property - I have pending patents for the six-gene pediatric leukemia stem cell score (https://pubmed.ncbi.nlm.nih.gov/31645648/) and other omics scores predictive of pediatric AML outcomes.
 
Mary Shago
No Relationships to Disclose
 
Karen R. Rabin
No Relationships to Disclose
 
Elizabeth A. Raetz
Research Funding - Pfizer (Inst)
Other Relationship - BMS
 
Meenakshi Devidas
Honoraria - Merck; Novartis
 
Cheng Cheng
No Relationships to Disclose
 
Anne L. Angiolillo
Employment - SERVIER
Consulting or Advisory Role - Jazz Pharmaceuticals
Travel, Accommodations, Expenses - SERVIER
 
Andrew J. Carroll
No Relationships to Disclose
 
Nyla A Heerema
No Relationships to Disclose
 
Ilaria Iacobucci
No Relationships to Disclose
 
Kelly W. Maloney
No Relationships to Disclose
 
Ching-Hon Pui
Leadership - Adaptive Biotechnologies
Honoraria - Amgen; Novartis
Consulting or Advisory Role - Adaptive Biotechnologies
Research Funding - National Cancer Institute
 
Nilsa C. Ramirez
No Relationships to Disclose
 
Stephen Hunger
Stock and Other Ownership Interests - Amgen; Merck (I)
Honoraria - Jazz Pharmaceuticals; Servier/Pfizer
 
Gang Wu
No Relationships to Disclose
 
Charles Grenfell Mullighan
Stock and Other Ownership Interests - Amgen
Honoraria - Amgen; Illumina
Consulting or Advisory Role - Beam Therapeutics; Faze Medicines; Illumina
Speakers' Bureau - Amgen; Pfizer
Research Funding - Abbvie; Loxo; Pfizer
Patents, Royalties, Other Intellectual Property - Inventor on a pending patent application related to gene-expression signatures for detection of underlying Philadelphia chromosome–like events and therapeutic targeting in leukemia (PCT/US2012/069228).; Marcus FISHER, Fatemeh KERAMATNIA, Kevin MCGOWAN, Jaeki MIN, Gisele A. NISHIGUCHI, Jeanine PRICE, Zoran RANKOVIC, Das SOURAV, Charles G. MULLIGHAN, Yunchao CHANG 2021 SUBSTITUTED N-(2-(2,6-DIOXOPIPERIDIN-3-YL)-1,3-DIOXOISOINDOLIN-5-YL)ARYLSULFONAMIDE ANAL (Inst); WO 2021/022076 A1 This Patent Highlight shows representative PROTAC compounds bound to JAK2, where ruxolitinib and baricitinib bind to the human JAK2 JH1. Furthermore, representative data illustrate protein degradation, cytotoxicity, and effect ofthe JAKS
Travel, Accommodations, Expenses - Amgen; Illumina
 
Mignon L. Loh
No Relationships to Disclose